Multi Cancer Early Detection Test

RM2,800.00

PACKAGE INCLUDES:

  • Complete medical report
  • Consultation by Health Screening Physician

Appointments

  • +604 238 3198/3199
  • appt@islandhospital.com

Terms & Conditions

  • Not valid in conjunction with other promotions or discounts.
  • Any optional test(s) are upon request and will be charged separately.
  • Any follow-up investigation or treatment or medication as a result of this screening will be charged by cash, debit or credit cards.
  • Available only to individuals who are independently mobile.
  • Results will be available in approximately 30 days. If the findings are negative, the report will be emailed. For positive findings, Island Hospital will contact you to schedule a consultation with our Health Screening Physicians.
  • The results may show mixed findings, either negative-positive or positive-negative. Further investigation with a clinical advisor is recommended.
  • Online purchase is limited to a maximum of (5) packages per order.
  • Appointments must be made at least three (3) working days in advance and are subject to availability.
  • Official payment confirmation and booking number must be produced on consultation day.
  • The purchase cannot be exchanged for any other items or services.
  • The decision is made by Island Hospital is final and non- negotiable.
  • Island Hospital reserves the rights to refuse any requests without giving reasons or change the terms and conditions or cancel any promotions at any time without notice.
  • This screening package is not exhaustive and may require further clinical screening for symptoms.
  • This screening is not a substitute for personalised medical advice and additional assessments may be necessary. Package(s) purchased is available for redemption up to 31st January 2025.

Description

The Multi-Cancer Early Detection (MCED) test is a simple blood test that can identify signs of over 20 different types and 110 subtypes of cancer. It’s especially useful because it can detect cancers that aren’t usually found with standard screèning tests. After taking a blood sample, the test looks for specific cancer-related changes in the DNA that floats freely in the bloodstream. If it finds anything suspicious, the test can even suggest where in the body the cancer might be starting.

This test is mainly recommended for people who are at higher risk for cancer, typically those who are 40 years old or older. It’s used along with other regular cancer screening methods to help catch cancer early. Catching cancer early can greatly improve treatment success and reduce the costs and complexities of later-stage treatments,

Tests

How Does the Test Work?

Our bodies shed DNA from all cells, including cancer cells, into the bloodstream. As cancer grows, the amount of this DNA in the blood increases. The Multi-Cancer Early Detection (MCED) test looks for specific changes in this DNA that suggest cancer is present. By analyzing these changes, the test can often tell where the cancer is starting to grow.

Understanding Your Test Results

Negative Result: No signs of cancer were found , but it's important to continue with other regular cancer screenings.
Positive Result: The test spotted something that might be cancer. More tests will be needed to confirm if it's really cancer.

How to Use the Test

1. You order the test at the clinics or hospitals.
2. The healthcare professional will collect 20 ml of your blood tor the test
3. The results are sent back to the your healthcare provider who will discuss the next steps with you.

Types of Cancer Detected

The test can detect various cancers including Lung, Colorectal, Liver, Breast, Uterine, Ovarian, Cervical, Blood, Gastric, Skin, Pancreatic, Prostate, Bladder, Kidney, and Brain cancers.
Remember, while this test can provide valuable insights, it's just one part of your overall health screening and care plan. Always discuss your options and what the results mean with your healthcare provider.

 

Breast Cancers

Basal (Triple-Negative) Carcinomas Ductal Carcinomas ER-Positive & PR-Positive Carcinomas HER-Positive Carcinomas Lobular Carcinomas Luminal Carcinomas Carcinomas Metastatic Breast Cancers Invasive lobular carcinoma Paget's disease of the breast Male breast cancer Papillary carcinoma  

Lung Cancers

Adenocarcinomas Malignant Pleural Mesotheliomas Non-Small Cell Lung Cancers (NSCLC) Squamous Cell Carcinomas Large Cell Carcinomas Small Cell Lung Cancers (SCLC)  

Colorectal Cancers

Adenocarcinomas  

Prostate Cancers

Adenocarcinomas Advanced Prostate Cancers Ductal Carcinomas  

Gastric Cancers

Adenocarcinomas Adenomas Gastrointestinal Stromal Tumors (GIST)  

Liver Cancers

Cholangiocarcinomas Hepatoblastomas Hepatocellular Carcinomas

Cervical Cancer

Squamous cell carcinoma Cervical adenocarcinomas  

Thyroid Cancer

Adenoma-Nodule-Goitre Anaplastic Carcinomas Papillary Carcinomas  

Head and Neck Cancer

Nasopharyngeal Cancer Oropharyngeal Cancer Laryngeal Cancer Salivary Cancer Oral Cancer Esophageal Cancer  

Bladder Cancers

Adenocarcinomas Transitional Cell Carcinomas Urothelial carcinoma  

Pancreatic Cancers

Ductal Adenocarcinomas Ductal Carcinomas  

Kidney Cancer

Clear Cell Renal Cell Carcinoma Wilms Tumor  

Ovarian Cancers

Germ cell tumors Ovarian stromal tumors Endometrioid Epithelial ovarian tumors Mucinous carcinoma Clear-cell adenocarcinoma Serous carcinoma Carcinosarcoma  

Melanomas

Cutaneous Melanomas Malignant Melanomas Mucosal Melanomas Ocular Melanomas Uveal Melanomas  

Leukemia

Acute Lymphoblastic Leukemia (ALL) Acute Myeloid Leukemia (AML) Acute Promyelocytic Leukemia (APML; APL) Atypical Chronic Myeloid Leukemia (CML) Chronic Lymphocytic Leukemia (CLL) Chronic Myeloid Leukemia (CML) Chronic Myelomonocytic Leukemia (CMML) Hairy Cell Leukemia Juvenile Myelomonocytic Leukemia Chronic Neutrophilic Leukemia  

Myeloid Neoplasms

Myelodysplastic Syndromes (MDS) Myeloproliferative Neoplasms (MPN) Multiple Myeloma Plasma Cell Myeloma Polycythemia Vera Primary Myelofibrosis Systemic Mastocytosis  

Endometrial Carcinomas

Epithelial Carcinomas Granulosa Cell Tumors Mixed Adenosquamous Carcinomas Mucinous Carcinomas Serous Carcinomas  

Lymphomas

Anaplastic Large Cell Lymphomas B Cell Lymphomas Burkitt Lymphomas Diffuse Large B Cell Lymphomas Follicular Lymphomas Hodgkin lymphoma Lymphocytic Lymphomas Mantle Cell Lymphomas Marginal Zone Lymphomas Mucosa-Associated Lymphoid Tissue (MALT) Lymphomas Non-Hodgkin Lymphomas Primary Cutaneous Lymphomas Small Lymphocytic Lymphomas T Cell Lymphomas  

Sarcoma

Askins Tumors Biphenotypic Sarcomas with Myogenic & Neural Differentiation Clear Cell Sarcomas Congenital (Infantile) Fibrosarcomas Desmoplastic Small Round Cell Tumors Ewing's Sarcomas Fibrosarcomas Myofibroblastic Sarcomas Rhabdomyosarcomas Small Round Cell Tumors  

Brain Cancers

Anaplastic Glial Tumors Astrocytomas Ependymomas Glioblastomas Gliomas Medulloblastomas Meningiomas Oligodendrogliomas

Frequently Asked Questions

  • What is the MCED test?
    The MCED test is a non-invasive blood test that identifies signs of over 110 types of cancer, some of which are not covered by routine screening methods.
  • How does the MCED test work?
    The test analyzes cell-free DNA (cfDNA) in the blood to detect cancer-related mutations and
    predicts the origin of cancer if found.
  • Who should consider taking the MCED test?
    It is recommended for individuals aged 40 or older and others at high risk, such as those with a family history of cancer or exposure to known risk factors.
  • How often should the MCED test be taken?
    Annual testing is recommended, but high-risk individuals may consider more frequent testing
    based on their healthcare provider’s advice.
  • Can I take the test if I am under 40 years old?
    Yes, younger individuals with elevated cancer risks can also benefit from the MCED test.
  • What cancers does the MCED test detect?
    It detects a wide range of cancers, including Lung, Colorectal, Liver, Breast, Uterine, Ovarian, Cervical, Blood, Gastric, Skin, Pancreatic, Prostate, Bladder, Kidney, and Brain cancers.
  • Can the MCED test replace traditional cancer screenings?
    No, it complements existing screening methods and should be part of a comprehensive health plan.
  • What are the benefits of early cancer detection?
    Early detection improves treatment success rates, enhances quality of life, and lowers healthcare costs.
  • What if I have no symptoms but test positive?
    Early detection often identifies asymptomatic cancers. Follow-up tests will help determine the next steps.
  • Can the test be useful for rare cancers?
    Yes, the MCED test covers many rare cancers not included in routine screenings.
  • Does the test detect childhood cancers?
    The MCED test primarily focuses on adult cancers but may detect some cancers that affect both children and adults.
  • Does it detect cancers with no symptoms?
    Yes, it excels in identifying asymptomatic cancers that might otherwise go undiagnosed.
  • Can it detect rare genetic cancers?
    Some rare genetic cancers may be identified, although specific genetic panels might be needed for confirmation.
  • Can it detect slow-growing cancers?
    Yes, the test detects DNA shed from cancers at any growth rate, though follow-up is essential for monitoring progression.
  • Can it detect cancers in organs like the pancreas or brain?
    Yes, the test detects hard-to-screen cancers, including pancreatic and brain tumors.
  • Does it detect blood cancers?
    Yes, it can identify various blood cancers such as leukemia and lymphoma.
  • What is the detection rate for ovarian cancer?
    The test has a sensitivity of 94.8% for ovarian cancer.
  • Does the test cover metastatic cancers?
    Yes, it can detect metastatic cancers by analyzing cancer-specific DNA mutations in the bloodstream.
  • How does it detect non-solid tumors like leukemia?
    It identifies specific mutations in circulating tumor DNA (ctDNA) associated with blood cancers.
  • Can it detect hereditary cancers?
    While it detects cancerous DNA, it does not replace genetic testing for hereditary cancer risks.
  • How accurate is the MCED test?
    The MCED test has an overall sensitivity of 83% and specificity of 95.4% across various cancer types.
  • Does the test detect all cancers?
    While it detects over 110 cancers, it may not identify all types. It complements other cancer screening tests.
  • What happens if the result is positive?
    A positive result indicates a potential cancer signal, and follow-up diagnostic tests are required to confirm the presence and location of cancer.
  • What does a negative result mean?
    A negative result means no cancer signal was found. However, routine screenings and health monitoring should continue.
  • Can the MCED test identify the cancer’s origin?
    Yes, it can predict the likely location of cancer in the body, aiding further diagnostic steps.
  • How is the MCED test performed?
    A healthcare professional draws 20 mL of blood, which is then analyzed in a certified laboratory.
  • Is the test painful?
    The procedure involves a simple blood draw, which may cause minimal discomfort.
  • How long does it take to get the results?
    Results are usually available within 7 to 14 working days.
  • Where can I take the MCED test?
    It is available at clinics, hospitals, or any authorized healthcare provider offering the service.
  • What are the sample requirements?
    Blood must be collected in EDTA tubes, and plasma samples should be processed promptly to prevent degradation.
  • Insurance and Cost
    Is the MCED test covered by insurance?
    Coverage depends on the insurance provider and specific policy terms. It is advisable to confirm with your insurer.
  • Can the MCED test save healthcare costs?
    Early detection allows for less invasive treatments and reduces the complexity and cost of latestage cancer management.
  • How do I prepare for the MCED test?
    No specific preparation is needed, such as fasting. Just ensure you arrive at your appointment wellrested.
  • Can the MCED test be performed during pregnancy?
    Yes, it is non-invasive and safe, though results should be interpreted with care in consultation with
    a healthcare provider.
  • Can I take the test if I am ill or recovering from an infection?
    Yes, you can take the test. The MCED test specifically detects cancer-related circulating tumor DNA (ctDNA), which is not influenced by infections, ensuring the accuracy of the results even if you
    are unwell.
  • Is the test available at home?
    Currently, the test requires a blood draw by a healthcare professional and is not offered as a homebased test.
  • How many times can I take the MCED test in a year?
    High-risk individuals may take it twice a year, but once annually is generally sufficient for most.
  • What is the recommended frequency for cancer survivors?
    Cancer survivors may take the test every six months or as recommended by their doctor to monitor recurrence.
  • Does the MCED test require follow-up consultations?
    Yes, regardless of the result, follow-up discussions with a healthcare provider are recommended.
  • What happens if the blood sample is insufficient?
    A second blood draw may be necessary to ensure accurate analysis.
  • Does the MCED test detect benign tumors?
    Yes, the MCED test can detect benign tumors as they may also release DNA into the bloodstream. Further diagnostic tests are required to differentiate between benign and malignant findings.
  • Can the test detect pre-cancerous conditions?
    Yes, it can pick up early changes that might indicate pre-cancerous conditions.
  • Is the MCED test recommended for smokers?
    Yes, smokers and individuals with chronic lung diseases are encouraged to undergo regular screenings, including the MCED test.
  • Should individuals with family cancer history take the test?
    Yes, those with a family history of cancer are at higher risk and can benefit from the MCED test.
  • Can cancer survivors take the MCED test?
    Yes, it helps monitor for potential recurrence or development of new cancers.
  • How is the sample shipped for testing?
    Blood and plasma can be shipped at room temperature.
  • What precautions are taken to prevent sample contamination?
    Samples are collected under sterile conditions to avoid contamination, ensuring reliable test results.
  • Where are the tests conducted?
    The analysis takes place in AGTC Genomics ISO 15189-certified laboratory at Bukit Jalil, Kuala Lumpur, ensuring high accuracy and reliability.
  • Can the test predict metastatic cancer?
    Yes, by analyzing cfDNA patterns, the test can detect cancers at various stages, including metastatic ones.
  • What is the sensitivity for major cancers like lung and breast cancer?
    Sensitivity for lung cancer is 93.3%, and for breast cancer, it is 96.8%, indicating high accuracy in detecting these cancers.
  • What are the limitations of the MCED test?
    It does not detect every cancer type and cannot fully replace other screening tools like
    mammograms or colonoscopies.
  • Can the test miss cancers?
    While it has high sensitivity, no test is perfect. Routine screenings remain essential.
  • How is MCED different from traditional cancer screenings?
    MCED uses a blood sample to detect multiple cancers, whereas traditional methods focus on specific types (e.g., mammograms for breast cancer).
  • Does the MCED test replace genetic cancer tests?
    No, genetic testing is needed to assess hereditary risks, whereas MCED focuses on detecting active cancers.
  • Can it replace imaging like CT scans?
    No, MCED complements imaging but cannot fully substitute it for diagnosis or monitoring.
  • What happens if MCED identifies a cancer signal, but imaging shows nothing?
    Further monitoring may be required, as some cancers may not yet be visible through imaging.
  • Does MCED identify cancer recurrence?
    Yes, it can be used to detect the recurrence of cancer in previously diagnosed individuals.
  • Can MCED detect cancer progression?
    While it provides early signals, progression monitoring may require follow-up with additional diagnostic tools.
  • How does MCED testing impact cancer survival rates?
    Early detection through MCED significantly improves survival rates by initiating treatment at earlier stages.
  • Are there financial assistance programs for MCED testing?
    Some labs and healthcare providers may offer financial aid or installment plans.
  • Can public healthcare cover the MCED test?
    In some countries, public healthcare systems may include it for high-risk individuals. Check with local policies.
  • Are employer wellness programs covering MCED tests?
    Some employers may offer coverage through wellness initiatives or corporate health programs.
  • Is the MCED test safe?
    Yes, it is non-invasive, requiring only a standard blood draw with minimal risks.
  • Is the test FDA-approved?
    The MCED test complies with international safety and accuracy standards. The technology used in the test is FDA-approved.
  • How is patient confidentiality maintained?
    All patient data is securely stored and shared only with authorized healthcare providers.
  • Is the MCED test covered under ISO standards?
    Yes, AGTC Genomics lab conducting the test is ISO 15189 and ISO 17025 certified, and comply to the College of American Pathologists (CAP) guidelines, ensuring quality and accuracy.
  • What are the storage requirements for blood samples?
    Samples must be stored in EDTA or Cell-Free DNA Blood Collection Tubes (Streck tubes) and transported under recommended conditions to maintain integrity.
  • How does MCED support personalized medicine?
    It provides insights into cancer origin, enabling personalized treatment plans.
  • What role does MCED play in preventative care?
    It identifies cancers early, often before symptoms arise, facilitating preventative healthcare strategies.
  • How do results integrate into treatment planning?
    Oncologists can use the results to guide decisions on imaging, biopsies, or treatments.
  • Does MCED reduce the need for invasive procedures?
    Yes, by detecting cancer early, it can potentially reduce the need for invasive biopsies.
  • How does the MCED test impact healthcare costs?
    Early detection reduces costs associated with late-stage cancer treatment and hospitalizations.
  • Does the test support clinical decision-making?
    Yes, it offers critical data to support healthcare providers in diagnosis and treatment.
  • How can MCED testing enhance cancer prevention programs?
    By detecting cancer early, it helps shift healthcare systems towards proactive rather than reactive care.
  • What is the role of MCED in oncology care pathways?
    MCED testing fits into the early detection and monitoring phase of oncology care, improving overall patient outcomes.
  • What is the global availability of MCED?
    MCED testing is available in several countries through authorized clinics and hospitals.
  • How does MCED improve patient quality of life?
    Early detection reduces treatment burdens, leading to better quality of life for patients.
  • Does MCED testing involve genetic counseling?
    While genetic counseling is not included, providers may recommend it based on test results.
  • How can MCED benefit rural healthcare systems?
    Its non-invasive nature makes it ideal for decentralized healthcare settings.
  • Can the test identify lifestyle-related cancers?
    Yes, it detects cancers linked to lifestyle factors like smoking, alcohol consumption, and obesity.
  • Is MCED testing suitable for international travelers?
    Yes, results can be shared with healthcare providers across borders if needed.
  • Can MCED testing reduce emergency hospital admissions?
    Yes, early detection reduces the need for emergency interventions by catching cancer early.
  • How does MCED align with national cancer control strategies?
    It fits well into national frameworks aiming to improve early detection and reduce cancer mortality rates.
  • What are the long-term benefits of MCED testing?
    It enables proactive healthcare, lowers mortality, and promotes efficient use of healthcare resources.

More Packages

Subscribe To Our Newsletter

    Stay updated with the latest news